BCMA CHO Recombinant Cell Line (High or Low Expression)

Only %1 left
Catalog #
79500
As low as $6,825 *

Cat # Size Price*

Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

BCMA CHO Cell Line is a clonal stable CHO cell line constitutively expressing full length human BCMA protein, also known as TNFRSF17, (Genbank #NM_001192). Surface expression of BCMA was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of BCMA expression, (High or Low), to mimic different stages of cancer target cells with various BCMA expression levels.

This product has been cited 3 times.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

Synonyms
Tumor necrosis factor receptor superfamily member 17, B-cell maturation protein, CD269, TNFRSF17, BCM, BCMA
Product Info
Storage and Usage
Citations3
Host Cell Line
CHO-K1 cells, Chinese Hamster Ovary, epithelial-like cells, adherent
Species
Human
Supplied As
Each vial contains >1 x 106 cells in 1 ml of Cell Freezing Medium (BPS Bioscience, #79796)
Materials Required But Not Supplied

Media Required for Cell Culture

Name Ordering Information
Thaw Medium 3 BPS Bioscience #60186
Growth Medium 3D BPS Bioscience #79539


Materials Required for Cellular Assay

Name Ordering Information
NFAT Reporter (Luc) – Jurkat Recombinant Cell Line BPS Bioscience #60621
Thaw Medium 2 BPS Bioscience #60184
Anti-BCMA/Anti-CD3 Bispecific Antibody BPS Bioscience #100689
96-well tissue culture-treated white clear-bottom assay plate  
PE-conjugated anti-human BCMA (CD269) antibody Biolegend #357504
ONE-Step™ Luciferase Assay System BPS Bioscience #60690
Luminometer  
Genbank #
NM_001192
UniProt #
Q02223
Mycoplasma Testing

The cell line has been screened to confirm the absence of Mycoplasma species.

Background

B-cell maturation antigen (BCMA), also known as CD269 or tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor (BAFF). BCMA is preferentially expressed in mature B lymphocytes and also on Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy because of its restricted expression in non-malignant tissue but almost universal expression on MM cells.  CAR (chimeric antigen receptor)-T BCMA cells are an autologous T cell product engineered by lentiviral transduction to express a fully human BCMA-specific CAR.  CAR-T cells targeting BCMA have pre-clinical anti-MM activity, and in 2017, the FDA granted BCMA CAR T-Cell immunotherapy breakthrough designation in Multiple Myeloma.

References

Ghosh A., et al. 2017 Leuk Lymphoma. 6:1-12
Sanchez E., et al., 2018   Expert Rev Mol Diagn. 7:1-11.
Sohail A., et al., 2018 Immunotherapy. 10(4):265-282.
Sidaway P., et al. 2016 Nat Rev Clin Oncol. 13(9):530.